GW Pharmaceuticals PLC- (GWPH) Holdings Cut by C WorldWide Group Holding A S

GW Pharmaceuticals PLC- (GWPH) Holdings Cut by C WorldWide Group Holding A S

C WorldWide Group Holding A S decreased its holdings in shares of GW Pharmaceuticals PLC- (NASDAQ:GWPH) by 8.7% in the 1st quarter, Holdings Channel reports. The fund owned 23,473 shares of the biopharmaceutical company’s stock after selling 2,229 shares during the quarter. C WorldWide Group Holding A S’s holdings in GW Pharmaceuticals PLC- were worth $3,957,000 at the end of the most recent quarter.

Other hedge funds have also bought and sold shares of the company. Federated Investors Inc. PA increased its stake in GW Pharmaceuticals PLC- by 14.2% during the third quarter. Federated Investors Inc. PA now owns 257,300 shares of the biopharmaceutical company’s stock worth $44,446,000 after acquiring an additional 32,000 shares during the last quarter. Deutsche Bank AG increased its stake in GW Pharmaceuticals PLC- by 18.2% during the fourth quarter. Deutsche Bank AG now owns 270,575 shares of the biopharmaceutical company’s stock worth $26,350,000 after acquiring an additional 41,593 shares during the last quarter. Tekla Capital Management LLC increased its stake in GW Pharmaceuticals PLC- by 45.3% during the fourth quarter. Tekla Capital Management LLC now owns 63,345 shares of the biopharmaceutical company’s stock worth $6,169,000 after acquiring an additional 19,747 shares during the last quarter. Osborn Williams & Donohoe LLC acquired a new stake in GW Pharmaceuticals PLC- during the first quarter worth $129,000. Finally, QCI Asset Management Inc. NY increased its stake in GW Pharmaceuticals PLC- by 86.2% during the fourth quarter. QCI Asset Management Inc. NY now owns 661 shares of the biopharmaceutical company’s stock worth $64,000 after acquiring an additional 306 shares during the last quarter. 79.28% of the stock is owned by institutional investors.

Several research analysts have recently commented on the company. BidaskClub upgraded GW Pharmaceuticals PLC- from a “hold” rating to a “buy” rating in a research report on Thursday. Zacks Investment Research upgraded GW Pharmaceuticals PLC- from a “hold” rating to a “strong-buy” rating and set a $198.00 price target for the company in a research report on Saturday, March 2nd. Cantor Fitzgerald restated an “overweight” rating and set a $229.00 price target (up from $196.00) on shares of GW Pharmaceuticals PLC- in a research report on Tuesday. Oppenheimer lowered GW Pharmaceuticals PLC- from an “outperform” rating to a “market perform” rating and set a $195.00 price target for the company. in a research report on Wednesday. Finally, Piper Jaffray Companies raised their price target on GW Pharmaceuticals PLC- from $185.00 to $210.00 and gave the stock an “overweight” rating in a research report on Tuesday. One investment analyst has rated the stock with a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $205.40.

In related news, COO Christopher J. Tovey sold 200,736 shares of GW Pharmaceuticals PLC- stock in a transaction on Tuesday, May 7th. The stock was sold at an average price of $16.14, for a total value of $3,239,879.04. Following the completion of the transaction, the chief operating officer now directly owns 203,239 shares in the company, valued at $3,280,277.46. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Adam D. George sold 258,324 shares of GW Pharmaceuticals PLC- stock in a transaction on Tuesday, May 7th. The shares were sold at an average price of $16.10, for a total value of $4,159,016.40. Following the completion of the transaction, the insider now owns 268,324 shares of the company’s stock, valued at $4,320,016.40. The disclosure for this sale can be found here. Over the last quarter, insiders sold 2,354,556 shares of company stock valued at $34,937,460. 5.50% of the stock is currently owned by company insiders.

GWPH opened at $182.76 on Friday. GW Pharmaceuticals PLC- has a 52 week low of $90.14 and a 52 week high of $196.00. The firm has a market cap of $5.29 billion, a PE ratio of -17.31 and a beta of 2.75. The company has a quick ratio of 6.34, a current ratio of 6.66 and a debt-to-equity ratio of 0.01.

GW Pharmaceuticals PLC- (NASDAQ:GWPH) last released its quarterly earnings results on Monday, May 6th. The biopharmaceutical company reported ($1.68) EPS for the quarter, topping the consensus estimate of ($2.48) by $0.80. GW Pharmaceuticals PLC- had a negative return on equity of 55.88% and a negative net margin of 1,734.86%. The business had revenue of $39.20 million during the quarter, compared to analyst estimates of $12.32 million. During the same period last year, the business posted ($3.12) earnings per share. The company’s quarterly revenue was up 1189.5% on a year-over-year basis. Equities research analysts predict that GW Pharmaceuticals PLC- will post -8.44 earnings per share for the current fiscal year.

GW Pharmaceuticals PLC- Profile

GW Pharmaceuticals plc, a biopharmaceutical company, focuses on discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant. Its lead product is Epidiolex, an oral medicine for the treatment of refractory childhood epilepsies, as well as for the treatment of Dravet syndrome, Lennox-Gastaut syndrome, tuberous sclerosis complex, and infantile spasms.

Read More: What is a Stop Order?

Want to see what other hedge funds are holding GWPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GW Pharmaceuticals PLC- (NASDAQ:GWPH).

Related posts

Leave a Comment